Posts by: Patricia Inacio, PhD

A new class of ingestible cannabinoid prodrugs known as cannabosides developed to treat colitis have shown positive results in preclinical studies, Vitality Biopharma has announced. Cannabosides are a modification of a novel ... Read more

July 14, 2017

FDA Considering Pfizer’s Rheumatoid Arthritis Therapy Xeljanz for Ulcerative Colitis, Too

News

U.S. regulators are considering extending their approval of Pfizer’s rheumatoid arthritis therapy Xeljanz to ulcerative colitis as well. That possibility surfaced when the Food and Drug Administration accepted Pfizer’s supplemental New Drug Application for ... Read more

July 12, 2017

Antibiotic Use in Final Stages of Pregnancy Increases IBD Risk in Offspring of Mice

News

Researchers at the University of Chicago Medicine found that mice genetically susceptible to developing inflammatory bowel disease (IBD) and treated with antibiotics during the final stages of pregnancy and ... Read more

May 30, 2017

Low Expression of MDR1 Gene Links Mitochondria Function to Severe Colitis, Mouse Study Shows

News

Researchers identified a gene, known as multidrug resistance-1 (MDR1), that may underlie the most severe and incurable forms of inflammatory bowel diseases (IBD). The findings may lead to the ... Read more

May 19, 2017

Gut Bacteria Change Can Signal That a Bowel Disease Is Developing, Study in Mice Reports

News

The mix of bacteria in the mucus lining the intestine begins changing long before symptoms of inflammatory bowel disease (IBD) show up, according to a study in mice at ... Read more

May 18, 2017May 18, 2017

Cd14 Gene Protects Mice Against Bowel Disease and Reduces Inflammation, Study Shows

News

The Cd14 gene protected mice against inflammatory bowel disease (IBD) by bolstering their intestinal barrier against harmful micro-organisms and reducing their gut inflammation, according to a study. Increasing the gene’s expression ... Read more

April 17, 2017

Innovative Microbiome-based IBD Therapeutics to Be Developed Under New Partnership

News

Takeda Pharmaceutical, a Japanese biopharmaceutical company, announced a strategic new collaboration with NuBiyota to develop Microbial Ecosystem Therapeutics, a new form of treatment for patients with gastroenterology disorders who fail to ... Read more

March 29, 2017March 29, 2017

Portuguese Blueberry Shows Potent Anti-Inflammatory Effect in Colitis Animal Model

News

An active ingredient of a specific type of Portuguese blueberry shows increased anti-inflammatory effects in the intestines of an animal model with colitis when compared to mesalamine (5-ASA), a ... Read more

March 27, 2017

European Union Approves Amgevita for Crohn’s Disease and Ulcerative Colitis

News

The European Union has approved Amgen‘s Amgevita, a biosimilar to Humira (adalimumab), as a treatment for inflammatory bowel diseases (IBDs) such as Crohn’s and ulcerative colitis. The European Commission decision ... Read more

March 24, 2017March 24, 2017

Review: Biologics Help Maintain Intestinal Mucosa Health in Crohn’s, Ulcerative Colitis Patients

News

Specific biologic treatments don’t only relieve symptoms but can also maintain intestinal health in patients with inflammatory bowel disease (IBD), according to a review that analyzed medicines approved by the U.S. ... Read more